PMID- 32079256
OWN - NLM
STAT- MEDLINE
DCOM- 20201116
LR  - 20201116
IS  - 1648-9144 (Electronic)
IS  - 1010-660X (Print)
IS  - 1010-660X (Linking)
VI  - 56
IP  - 2
DP  - 2020 Feb 17
TI  - Combined Effect of HPV and Several Gene SNPs in Laryngeal Cancer.
LID - 10.3390/medicina56020081 [doi]
LID - 81
AB  - Background and objectives: Laryngeal squamous cell carcinoma (LSCC) is one of the 
      most common head and neck tumors. The molecular mechanism of LSCC remains 
      unclear. The aim of this study was to evaluate the prevalence of Human 
      papillomavirus (HPV) and single nucleotide polymorphisms (SNPs) of TP53, MDM2, 
      MDM4, MTHFR, CASP8, and CCR5 genes in LSCC, and to assess their correlations with 
      patient survival. Materials and Methods: 49 LSCC patients were enrolled in this 
      study. PCR and qRT-PCR were used to detect, identify, and quantify HPV. SNPs were 
      genotyped using PCR and PCR-RFLP. Results: By analyzing the interactions of the 
      SNPs of the genes with clinical parameters, the majority of patients with lymph 
      node status (N1,2) were identified as carriers of MDM2 T/G, CASP8 ins/del, CCR5 
      wt/wt SNP. Cluster analysis showed that patients with MDM2 T/T SNP survive longer 
      than patients identified as CASP8 ins/ins, MTHFR C/C, and MDM4 A/A variant 
      carriers; meanwhile, LSCC patients with MDM2 T/T polymorphic variant had the best 
      survival. Multivariate analysis showed that HPV-positive patients without 
      metastasis in regional lymph nodes (N0) and harboring CASP8 ins/del variant had 
      the best survival. Meanwhile, HPV-negative patients with identified metastasis in 
      lymph nodes (N1 and N2) and CASP8 ins/del variant had poor survival. Conclusions: 
      This finding suggests patients survival prognosis and tumor behavior are 
      different according HPV status, SNP variants, and clinical characteristics of the 
      LSCC.
FAU - Stumbryte-Kaminskiene, Ausra
AU  - Stumbryte-Kaminskiene A
AD  - Biobank, National Cancer Institute, P. Baublio 3b, LT-08406 Vilnius, Lithuania.
FAU - Gudleviciene, Zivile
AU  - Gudleviciene Z
AD  - Biobank, National Cancer Institute, P. Baublio 3b, LT-08406 Vilnius, Lithuania.
FAU - Dabkeviciene, Daiva
AU  - Dabkeviciene D
AD  - Laboratory of Clinical Oncology, National Cancer Institute, P. Baublio 3b, 
      LT-08406 Vilnius, Lithuania.
FAU - Mackeviciene, Irina
AU  - Mackeviciene I
AD  - Department of Head and Neck Surgery and Oncology, National Cancer Institute, 
      Santariskiu 1, LT-08660 Vilnius, Lithuania.
LA  - eng
PT  - Journal Article
DEP - 20200217
PL  - Switzerland
TA  - Medicina (Kaunas)
JT  - Medicina (Kaunas, Lithuania)
JID - 9425208
RN  - 0 (CCR5 protein, human)
RN  - 0 (Cell Cycle Proteins)
RN  - 0 (MDM4 protein, human)
RN  - 0 (Proto-Oncogene Proteins)
RN  - 0 (Receptors, CCR5)
RN  - 0 (TP53 protein, human)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - EC 1.5.1.20 (MTHFR protein, human)
RN  - EC 1.5.1.20 (Methylenetetrahydrofolate Reductase (NADPH2))
RN  - EC 2.3.2.27 (MDM2 protein, human)
RN  - EC 2.3.2.27 (Proto-Oncogene Proteins c-mdm2)
RN  - EC 3.4.22.- (CASP8 protein, human)
RN  - EC 3.4.22.- (Caspase 8)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Carcinoma, Squamous Cell/*genetics
MH  - Caspase 8/analysis
MH  - Cell Cycle Proteins/analysis
MH  - Female
MH  - Humans
MH  - Laryngeal Neoplasms/*genetics/pathology
MH  - Male
MH  - Methylenetetrahydrofolate Reductase (NADPH2)/analysis
MH  - Middle Aged
MH  - Papillomavirus Infections/*complications/genetics
MH  - Polymorphism, Single Nucleotide/genetics
MH  - Prognosis
MH  - Proto-Oncogene Proteins/analysis
MH  - Proto-Oncogene Proteins c-mdm2/analysis
MH  - Receptors, CCR5/analysis
MH  - Tumor Suppressor Protein p53/analysis
PMC - PMC7074362
OTO - NOTNLM
OT  - human papillomavirus
OT  - laryngeal squamous cell carcinoma
OT  - multivariate analysis
OT  - patient survival
OT  - single nucleotide polymorphisms
COIS- Ethics approval and consent to participate: All patients included in this study 
      have signed an Informed patient consent approved by the Vilnius Regional 
      Committee of Biomedical Research (Lithuania, 2013-06-11 permission No. 
      158200-13-638-204). Consent for publication: Not Applicable. Availability of data 
      and materials: All data generated or analyzed during this study are included in 
      this published article and its supplementary information files. Competing 
      interests: The authors declare that they have no competing interests.
EDAT- 2020/02/23 06:00
MHDA- 2020/11/18 06:00
PMCR- 2020/02/17
CRDT- 2020/02/22 06:00
PHST- 2019/12/26 00:00 [received]
PHST- 2020/02/11 00:00 [revised]
PHST- 2020/02/12 00:00 [accepted]
PHST- 2020/02/22 06:00 [entrez]
PHST- 2020/02/23 06:00 [pubmed]
PHST- 2020/11/18 06:00 [medline]
PHST- 2020/02/17 00:00 [pmc-release]
AID - medicina56020081 [pii]
AID - medicina-56-00081 [pii]
AID - 10.3390/medicina56020081 [doi]
PST - epublish
SO  - Medicina (Kaunas). 2020 Feb 17;56(2):81. doi: 10.3390/medicina56020081.